The goal of this pilot program sponsored by the Data Science Working Group (DSWG) of the
Legorreta Cancer Center is to seed innovative data science methods and applications that address
key questions in cancer. This pilot award will support a Brown-affiliated team comprising at least one
co-PI who identifies primarily as a data scientist and one co-PI who identifies primarily as a basic,
translational, clinical, or behavioral researcher. The goal of the pilot should be to answer important
cancer-related questions based on existing or newly created data resources. Priority will be given to
proposals that use or develop innovative or creative new methods for analysis, visualization, design,
etc. As well as, to projects that focus on RI or healthcare disparities in RI. These pilot funds are also
intended to enable sufficient preliminary work to support a subsequent R01-equivalent grant
application to the NCI.

Due: December 6, 2024

View the RFA

Overview: This funding announcement aims to support promising and impactful basic and translational research by fostering collaboration between basic scientists and clinicians. The bench-to-bedside and bedside-to-bench approach is designed to effectively translate innovative ideas into practical applications for patients and the wider population. 

Eligible Investigators: Members of the Legorreta Cancer Center, either directly associated with Brown University or affiliated hospital campuses, are eligible to serve as Principal Investigators (PIs) for the grant. Co-investigators and collaborators may include Cancer Center members, individuals from outside academic institutions, or pharmaceutical companies who can meaningfully contribute to the scientific questions or their clinical translation. Non-members are welcome to contact Ms. Shiyoko Cothren to become Cancer Center members before applying for this funding. 

Available Support: We anticipate that at least four projects will receive funding for one year, with a minimum of $25K in direct costs per project. Applicants must clearly justify the need for support and outline the expected impact of their research. Funds will be allocated directly to the research, with no allowance for indirect costs or PI salary support.

Due: Thursday January 2nd, 2025 by 5pm

View the RFA

Unlimited funding, Rolling application 

Bold ideas to help children with brain tumors can come at any time. The Pediatric Brain Tumor Foundation accepts and evaluates requests for research funding on an ongoing basis throughout the year so that researchers are able to develop these ideas into the next scientific breakthrough. There are no deadlines, and we encourage investigators to apply at their earliest convenience.

Pediatric Brain Tumor Foundation Research Grant

The American Cancer Society (ACS) aims to improve the lives of people with cancer and their families through advocacy, research, and patient support and to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer.

The ACS invites applications for the Clinician Scientist Development Grant (CSDG) program, which supports full-time faculty members in becoming independent investigators as clinician-scientists. This grant is designed for people trained primarily as clinicians who want to maintain clinical practice and conduct cancer research.

Grants of $135,000 a year for direct costs plus 8 percent allowable indirect costs will be awarded for three to five years.

To be eligible, applicants must work at a U.S. academic institution or eligible nonprofit, have a doctoral degree, an active clinical license, and participate in clinical care, not be a current or former primary investigator (PI) of an individual mentored training grant, and have not had an R-level or equivalent grant as PI.

For complete program guidelines and application instructions, see the American Cancer Society website.

American Cancer Society RFP

METAvivor is pleased to announce the opening of our 2025 Award Cycle. METAvivor Research and Support Inc. is a charitable organization whose mission includes funding basic, translational, and clinical research with the goal of eradicating death due to metastatic breast cancer (MBC) by relegating it to a chronic manageable disease. METAvivor’s research program was established in 2009 to specifically fund research focused on treating established breast cancer metastases to improve outcomes for stage IV metastatic breast cancer patients.

For 2025, METAvivor will be accepting letters of intent in the following categories:
Translational - $450,000 over three years, opens February 5, 2025
Early Career - $200,000 over two years, opens February 6, 2025
Quality of Life - $200,000 over two years, opens February 7, 2025

Researchers: A training Q&A will take place on Monday, February 10th at 1:00pm Eastern / 12:00pm Central. Register for the training here.

Visit Application Portal

Established in 1936, the Charles A. King Trust was created to “support and promote the investigation of human disease and the alleviation of human suffering through improved treatment.” The Charles A. King Trust Postdoctoral Fellowship Program provides funding to postdoctoral fellows and mentored clinician scientists in the mid to late stages of their research training in basic and preclinical science, and clinical, health services, population health, and implementation research to help them become independent investigators in biomedical research. Through the fellowship program, grants ranging from $194,100 to $215,000 over two years, inclusive of stipend, fringe, and a $25,000 annual flexible expense allowance will be awarded. The program supports research across biomedical fields that focuses on the causes of human disease with the mission of improving treatment. 

Link to complete RFP

The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts. A description of the teams granted Endeavor Awards in 2023 can be found here.

Award Amount: $3

LOI due September 3, 2025

View RFA

The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.

Application Deadline: July 1, 2025

View the RFA